Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease

Journal of Crohn's and Colitis

Volumn 6, Issue 1, 2012, Pages 108-111

  Steenholdt, Casper ^a   Svenson, Morten ^b   Bendtzen, Klaus ^b,c   Thomsen, Ole Østergaard ^a   Brynskov, Jørn ^a   Ainsworth, Mark Andrew ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Biomonitor A/S   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Acute severe infusion reaction; Adalimumab; Adverse event; Crohn's disease; Delayed reaction; Infliximab

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; HYDROCORTISONE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB;

ABDOMINAL PAIN; ADULT; ANAPHYLAXIS; ARTICLE; BLOOD SAMPLING; CASE REPORT; CORTICOSTEROID THERAPY; CROHN DISEASE; CROSS REACTION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPNEA; ENDOSCOPY; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOGENICITY; MALAISE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; URTICARIA;

ANAPHYLAXIS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; MIDDLE AGED;

EID: 84855930008     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.08.001     Document Type: Article

References (20)

1. Miehsler W., Novacek G., Wenzl H., Vogelsang H., Knoflach P., Kaser A., Dejaco C., Petritsch W., Kapitan M., Maier H., Graninger W., Tilg H., Reinisch W.A. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010, 4:221-256.
2. Clark M., Colombel J.F., Feagan B.C., Fedorak R.N., Hanauer S.B., Kamm M.A., Mayer L., Regueiro C., Rutgeerts P., Sandborn W.J., Sands B.E., Schreiber S., Targan S., Travis S., Vermeire S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007, 133:312-339.
3. Stallmach A., Hagel S., Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010, 24:167-182.
4. Vermeire S., Van A.G., Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009, 23:101-112.
5. Maggi E., Vultaggio A., Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011, 7:55-63.
6. Allez M., Karmiris K., Louis E., Van A.G., Ben-Horin S., Klein A., Van der Woude J., Baert F., Eliakim R., Katsanos K., Brynskov J., Steinwurz F., Danese S., Vermeire S., Teillaud J.L., Lemann M., Chowers Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010, 4:355-366.
7. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789.
8. Steenholdt C., Bendtzen K., Brynskov J., Thomsen O.O., Ainsworth M.A. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011, 46:310-318.
9. Steenholdt C., Bendtzen K., Brynskov J., Thomsen O.O., Ainsworth M.A. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011, 46:310-318.
10. Svenson M., Jacobi H.H., Bodtger U., Poulsen L.K., Rieneck K., Bendtzen K. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. Mol Immunol 2003, 39:603-612.
11. Steenholdt C., Svenson M., Bendtzen K., Thomsen O.O., Brynskov J., Ainsworth M.A. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 34:51-58.
12. Cassinotti A., Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009, 15:1264-1275.
13. Candon S., Mosca A., Ruemmele F., Goulet O., Chatenoud L., Cezard J.P. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006, 118:11-19.
14. Vultaggio A., Matucci A., Nencini F., Pratesi S., Parronchi P., Rossi O., Romagnani S., Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657-661.
15. Sampson H.A., Mendelson L., Rosen J.P. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992, 327:380-384.
16. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98:1315-1324.
17. Han P.D., Cohen R.D. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004, 64:1767-1777.
18. Nikas S.N., Voulgari P.V., Drosos A.A. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007, 26:787-788.
19. Ternant D., Aubourg A., Magdelaine-Beuzelin C., Degenne D., Watier H., Picon L., Paintaud G. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008, 30:523-529.
20. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., Olson A., Bao W., Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.